What to Know About Wegovy: Dosing, Results & Safety

Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly injection approved for long-term weight management in adults and adolescents aged 12 and older with obesity or overweight with at least one weight-related condition. In real-world use, people taking Wegovy lose roughly 13 to 14 percent of their body weight within the first six months, with losses reaching around 18 to 20 percent by one to two years. But the numbers alone only tell part of the story, because how you dose it, what it does beyond the scale, what side effects to expect, and what happens if you stop all matter as much as the headline weight loss.

How Wegovy Works in the Brain and Gut

Semaglutide mimics a hormone called GLP-1 that your gut naturally releases after eating. The drug’s weight-loss effects come primarily from the brain, not the stomach. It acts on GLP-1 receptors in the hypothalamus and brainstem, which are regions that regulate appetite, hunger signals, and how rewarding food feels.¹ People on semaglutide consistently report feeling less hungry, getting full sooner, having fewer food cravings, and feeling more in control of what they eat.²

A common assumption is that Wegovy works mainly by slowing down digestion, making food sit in your stomach longer. Research tells a different story. When tested at 20 weeks of treatment, semaglutide 2.4 mg showed no meaningful evidence of delayed gastric emptying. Researchers believe any early slowing of the stomach wears off relatively quickly with long-acting GLP-1 drugs, a phenomenon called tachyphylaxis. The sustained weight loss appears to be driven instead by reduced calorie intake through changes in how the brain processes appetite and food reward.² Newer imaging studies have confirmed that semaglutide reaches GLP-1 receptors in brain regions normally protected by the blood-brain barrier after repeated dosing, including areas of the hypothalamus involved in energy balance.³

The Dose Escalation Schedule

Wegovy is not a drug you start at full strength. The label calls for a gradual monthly dose escalation over 16 weeks: you begin at 0.25 mg once weekly, move to 0.5 mg after a month, then 1.0 mg, then 1.7 mg, and finally the maintenance dose of 2.4 mg. This slow ramp-up exists to reduce gastrointestinal side effects, which tend to be worst during the early weeks and at each dose increase. In a real-world study of commercially insured adults, about 84 percent of patients who stayed on semaglutide 2.4 mg eventually reached the maximum dose.⁴

In practice, though, many people deviate from that neat monthly schedule. A large study of insured U.S. adults found that most semaglutide users had strayed from the recommended dose-escalation timeline within the first five months.⁵ Some people move up more slowly because of nausea or other side effects, and some clinicians keep patients at a lower dose longer if they are losing weight satisfactorily. There is nothing inherently wrong with a slower escalation, but skipping doses or going off and on erratically tends to bring back the worst of the gastrointestinal symptoms each time.

Weight Loss Results in the Real World

Clinical trials of Wegovy produced impressive numbers, but what matters more for most people is what happens outside the controlled setting of a study. A large real-world analysis of patients using a digital self-support app alongside semaglutide 2.4 mg found that people with a BMI of 30 or higher lost an average of about 13 percent of their body weight at six months, roughly 18 percent at one year, and around 21 percent at 18 to 24 months.⁶ A separate real-world study (SHAPE) looking at patients without type 2 diabetes found a mean weight loss of about 14 percent at one year with semaglutide 2.4 mg.⁴

One reassuring finding is that the drug appears to work similarly regardless of whether you have diabetes or prediabetes. A post hoc analysis of three randomized trials found that the weight loss difference between semaglutide and placebo was broadly comparable in people with type 2 diabetes, prediabetes, and no diabetes, with no statistically significant differences between those groups.⁷ People with diabetes did have numerically slightly lower weight loss, which is a pattern seen with many obesity drugs, but the gap was not large enough to be statistically meaningful.

What Happens to Fat Versus Muscle

Any time you lose a significant amount of weight, some of that loss comes from lean tissue, including muscle. This is not unique to Wegovy, but it is a legitimate concern, especially for older adults or anyone already low on muscle mass. A dedicated body-composition study (SEMALEAN) tracked what happened over 12 months on semaglutide. Total fat mass dropped by about 19 percent, while lean mass declined by about 3 kilograms in the first seven months and then stabilized through month 12. The proportion of lean mass relative to total body mass actually increased over the course of treatment, meaning people became leaner in relative terms even though they lost some absolute muscle.⁸

A large routine-care analysis comparing semaglutide and tirzepatide found that a pattern of heavy weight loss combined with substantial lean-mass decline (more than 20 percent total weight loss with more than 5 percent lean-body-mass loss) occurred in roughly 7 percent of semaglutide users during the first year.⁹ Higher doses and longer exposure were linked to greater lean-mass decline in both drug groups. Resistance training and adequate protein intake remain the most practical ways to protect muscle during treatment, and these are worth discussing with your provider before you start.

Researchers are also exploring pharmaceutical ways to preserve muscle. A phase 2b trial tested a drug called enobosarm (a selective androgen receptor modulator) alongside Wegovy and found that patients taking the combination lost about 71 percent less lean mass than those on Wegovy alone, with better preservation of functional strength measured by stair-climbing power.¹⁰ Other approaches in the pipeline include myostatin-targeting therapies and gene-silencing treatments, though none are yet approved for this use.¹¹

Cardiovascular Benefits

The most significant finding beyond weight loss came from the SELECT trial, which enrolled more than 17,600 adults with obesity and existing cardiovascular disease but without diabetes. Semaglutide reduced the rate of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20 percent compared to placebo over a mean follow-up of about 40 months.¹²¹³ This was not a marginal finding. It was the first time any weight-management drug demonstrated a cardiovascular benefit of this magnitude in people without diabetes, and it shifted how many cardiologists think about obesity treatment.

It is worth noting that the cardiovascular benefit was seen in people who already had heart disease. Whether the same protection applies to people with obesity who do not yet have cardiovascular disease has not been tested in a dedicated outcomes trial. The drug clearly improves blood pressure, cholesterol, and blood sugar, all of which are risk factors for heart disease, but proving that those improvements translate into fewer heart attacks and strokes in a lower-risk population requires its own study.

Effects on Liver Health

Fatty liver disease, now called metabolic dysfunction-associated steatotic liver disease (MASLD), is extremely common in people with obesity. Semaglutide has shown clear benefits for the liver. A meta-analysis of placebo-controlled trials found that semaglutide more than doubled the likelihood of resolving the inflammatory form of the disease (MASH) without worsening fibrosis, while also significantly lowering liver enzyme levels.¹⁴ The catch is that improvement in fibrosis itself, the scarring that makes liver disease dangerous long-term, was not statistically significant, though the trend favored semaglutide.

These liver findings led to semaglutide receiving accelerated FDA approval for the treatment of MASH, making it one of only two drugs approved for that condition.¹⁵ If your doctor has flagged elevated liver enzymes or fatty liver on an ultrasound, this is a point worth discussing when considering Wegovy.

Side Effects You Should Expect

Gastrointestinal symptoms are the dominant side effect. Nausea, vomiting, diarrhea, constipation, and abdominal pain affect the majority of people at some point during treatment. In the STEP TEENS trial of adolescents, 62 percent of those on semaglutide reported gastrointestinal symptoms versus 42 percent on placebo, and similar rates have been seen in adult trials.¹⁶ Most of these symptoms are mild to moderate and tend to improve over weeks, particularly if you follow the gradual dose escalation. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help, though formal evidence for specific dietary strategies during GLP-1 treatment remains thin.

More serious but less common risks include:

Pancreatitis: Inflammation of the pancreas has been reported in a small number of users. Severe abdominal pain that radiates to your back warrants immediate medical attention.
Gallbladder disease: Gallstones and related problems occur at elevated rates with rapid weight loss from any cause, and Wegovy is no exception. In the adolescent trial, 4 percent of semaglutide patients developed gallstones versus none on placebo.¹⁶
Thyroid concerns: Wegovy carries a boxed warning about thyroid C-cell tumors based on animal studies in rodents. In humans, across large studies, thyroid cancer cases have been very rare, each constituting less than one percent of study participants, and systematic reviews have found no significant risk signal associated with semaglutide.¹⁷ Still, Wegovy is contraindicated if you have a personal or family history of medullary thyroid carcinoma or a condition called multiple endocrine neoplasia syndrome type 2.
Eye and other rare effects: Ophthalmologic concerns and other rare adverse events have been reported but remain uncommon.¹⁸

The gastrointestinal side effects are also reflected in meta-analyses of semaglutide for fatty liver disease, where the drug roughly tripled the odds of GI-related adverse events compared to placebo.¹⁹ In plain terms: most people will have some stomach trouble, especially early on. For most, it is manageable. For some, it is bad enough to stop treatment.

What Happens When You Stop

This is the part of the Wegovy conversation that gets uncomfortable. In the STEP 1 trial extension, participants who stopped semaglutide after 68 weeks regained an average of about two-thirds of the weight they had lost over the following year. By week 120, former semaglutide users retained a net loss of about 5.6 percent from their original starting weight, compared to a loss of nearly 15 percent at the time they stopped the drug. Cardiometabolic improvements in blood pressure, blood sugar, and cholesterol also drifted back toward baseline after stopping.²⁰

This pattern is not unique to Wegovy. Obesity is a chronic condition driven by biological regulation of body weight, and when the drug that is helping override those regulatory signals is removed, the body’s set point reasserts itself. The practical implication is that most people will need to stay on treatment indefinitely to maintain the full benefit. That makes cost and long-term access serious considerations, not just nice-to-haves.

Wegovy Versus Ozempic, and Versus Tirzepatide

Wegovy and Ozempic are the same molecule, semaglutide, packaged and approved differently. Ozempic is approved for type 2 diabetes management and comes in doses up to 2.0 mg, while Wegovy is approved for weight management and goes up to 2.4 mg.²¹ Some people use Ozempic off-label for weight loss, often because of insurance coverage differences, but the dose ceiling is lower and the titration pens are configured differently.

The more interesting comparison is with tirzepatide (brand name Zepbound for weight management, Mounjaro for diabetes). Tirzepatide targets both the GLP-1 and GIP receptors, and head-to-head data consistently shows it produces more weight loss than semaglutide. A real-world six-month study found that tirzepatide-treated patients lost about 11 percent of their weight compared to about 9 percent with semaglutide, an adjusted difference of roughly 2.3 percentage points favoring tirzepatide.²² A Bayesian network meta-analysis of clinical trials found that the higher doses of tirzepatide (10 mg and 15 mg) produced about 5 to 6 additional percentage points of weight loss compared to semaglutide.²³

More weight loss is not always straightforwardly better, though. The routine-care body-composition analysis found that the pattern of aggressive weight loss combined with significant lean-mass decline was more common with tirzepatide than with semaglutide (about 10 percent versus 7 percent of patients).⁹ Semaglutide also has the SELECT cardiovascular outcomes data behind it, which tirzepatide does not yet have for a non-diabetes population. Choice between the two often comes down to availability, insurance coverage, individual tolerance, and how much weight loss your doctor thinks is appropriate for your situation.

Use in Adolescents

Wegovy is approved for adolescents aged 12 and older, based on the STEP TEENS trial of 180 participants. Teenagers receiving semaglutide saw their BMI drop by an average of about 16 percent over 68 weeks, compared to a slight increase in the placebo group. Nearly three-quarters of adolescents on semaglutide achieved at least 5 percent weight loss, and about 44 percent were reclassified to a normal or overweight BMI category by the end of the trial.²⁴¹⁶ The trial also showed improvements in cardiometabolic risk factors including waist circumference, blood sugar markers, and lipid levels.

Side effects in adolescents mirrored those in adults: gastrointestinal complaints were the most common, affecting 62 percent of the treatment group. Serious adverse events occurred in about 11 percent of the semaglutide group versus 9 percent on placebo, and 5 percent discontinued due to adverse events.¹⁶ The long-term implications of starting a GLP-1 drug in adolescence, particularly regarding growth, bone development, and whether teens will need to stay on the drug indefinitely, are still being studied.

Cost, Access, and Staying on Treatment

The biggest barrier for most people is not side effects but cost. At list price, Wegovy runs over $1,300 per month without insurance, and many insurance plans either do not cover weight-management drugs or impose significant cost-sharing. This has real consequences for outcomes. In a study of commercially insured adults, nearly half had discontinued semaglutide by the fifth month. Discontinuation was strongly tied to out-of-pocket cost: rates were about 41 percent among those with the lowest copays (under $54 per month) and rose to 51 percent in the highest copay group (over $161 per month). Lower household income and education level were also associated with higher dropout rates.⁵

There is some encouraging news on persistence trends. One-year persistence rates for semaglutide have been climbing steadily as supply issues eased and familiarity with the drug increased: from about 33 percent in 2021 to roughly 59 percent among people who started in the first half of 2024.²⁵ That still means about four in ten people stop within a year, but the trajectory suggests that as access and support improve, more people are sticking with treatment long enough to see meaningful results.

Emerging Research on Alcohol and Reward

One of the more unexpected lines of research around semaglutide involves its effects on alcohol. Animal studies have shown that semaglutide dampens the internal cues that signal alcohol’s effects in the brain, essentially making alcohol feel less rewarding. In one experiment, repeated semaglutide treatment maintained this dampening effect over a 15-day period, but the effect disappeared within three days of stopping the drug.²⁶ This aligns with widespread anecdotal reports from Wegovy users who say they simply feel less interested in drinking. Human clinical trials are now underway to determine whether GLP-1 drugs could become a treatment for alcohol use disorder. None of this is approved or established yet, but it points to the broader ways these drugs interact with the brain’s reward circuitry, which is likely also why food cravings diminish so reliably.